A detailed history of Sawtooth Solutions, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sawtooth Solutions, LLC holds 22,783 shares of VRTX stock, worth $11.4 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares
22,783
Previous 18,452 23.47%
Holding current value
$11.4 Million
Previous $6.42 Million 44.48%
% of portfolio
0.25%
Previous 0.21%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $1.49 Million - $1.78 Million
4,331 Added 23.47%
22,783 $9.27 Million
Q3 2023

Oct 19, 2023

SELL
$338.18 - $362.46 $4,058 - $4,349
-12 Reduced 0.06%
18,452 $6.42 Million
Q2 2023

Jul 26, 2023

BUY
$314.42 - $351.91 $2.88 Million - $3.23 Million
9,171 Added 98.69%
18,464 $6.5 Million
Q1 2023

Apr 27, 2023

BUY
$283.23 - $323.1 $1.46 Million - $1.67 Million
5,167 Added 125.23%
9,293 $2.93 Million
Q4 2022

Feb 02, 2023

SELL
$285.76 - $321.48 $72,868 - $81,977
-255 Reduced 5.82%
4,126 $1.19 Million
Q3 2022

Oct 12, 2022

BUY
$273.83 - $305.53 $134,176 - $149,709
490 Added 12.59%
4,381 $1.27 Million
Q2 2022

Jul 19, 2022

BUY
$234.96 - $292.55 $107,376 - $133,695
457 Added 13.31%
3,891 $1.1 Million
Q1 2022

May 20, 2022

BUY
$221.42 - $260.97 $255,075 - $300,637
1,152 Added 50.48%
3,434 $897,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $403,936 - $509,912
2,282 New
2,282 $502,000
Q3 2020

Nov 04, 2020

SELL
$255.65 - $303.1 $417,220 - $494,659
-1,632 Closed
0 $0
Q2 2020

Aug 06, 2020

BUY
$225.48 - $295.8 $367,983 - $482,745
1,632 New
1,632 $474,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Sawtooth Solutions, LLC Portfolio

Follow Sawtooth Solutions, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sawtooth Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sawtooth Solutions, LLC with notifications on news.